19 Novembre 2026

Psicologia Punto One | Psicologia e Psicologi nel Web

Menu

Menu

SCHEDA SCIENTIFICA2026Studio randomizzato

Effects of Supplementation With Genistein on the Progression of Cognitive Decline in Patients With Mild Cognitive Impairment Due to Alzheimer Disease: Protocol for a Randomized Controlled Trial.

Francisco Javier López Román, Manuel Sebastián, Silvia Pérez-Piñero, Ingrid Hernández-Manzano, Olga Laosa-Zafra, Leocadio Rodríguez-Mañas, Francisco José Tarazona-Santabalbina, Consuelo Borrás, José Viña

JMIR research protocols · 2026

Abstract originale

BACKGROUND: Mild cognitive impairment (MCI) may represent a prodromal stage of Alzheimer disease, but interventions to delay progression remain limited. Genistein is a phytoestrogenic isoflavone with potential effects on several pathways implicated in Alzheimer disease. We previously showed that genistein reverses cognitive decline and lowers brain amyloid β (Aβ) in the Aβ precursor protein/presenilin 1 double transgenic (AβPP/PS1) model of Alzheimer disease. OBJECTIVE: The study aimed to evaluate whether oral genistein supplementation affects cognitive decline in patients with MCI due to Alzheimer disease, compared with a placebo, and to assess its effects on brain amyloid burden and plasma biomarkers. METHODS: This multicenter, randomized, double-blind, placebo-controlled trial will include adults aged 50 years or older with MCI due to Alzheimer disease. Participants will be randomized 1:1 to genistein (200 mg/day) or a maltodextrin-based placebo for 18 months. The primary outcome is change in the Integrated Alzheimer's Disease Rating Scale (iADRS) score. Secondary outcomes include other neuropsychological measures, amyloid burden measured by 18F-flutemetamol positron emission tomography, plasma Alzheimer disease biomarkers, and safety. Outcomes will be assessed at baseline, midstudy, and study completion. Analyses are planned in the intention-to-treat and per-protocol populations using repeated-measures analysis of variance, with time as the within-participant factor, treatment group as the between-participant factor, and study site as a covariate. RESULTS: Funding for the study began in January 2024 and was provided by Trugon Investigaciones (AIE) through a grant to the Chair of Geroscience at Universidad Católica de Murcia. Data collection began in July 2026 and is projected to conclude in January 2029, consistent with the estimated 30-month study duration. Enrollment is expected to last approximately 9 months. As of August 5, 2026, a total of 4 participants had been recruited. Data analysis has not begun and will start after the final participant completes follow-up. Results are expected to be published in late 2029. CONCLUSIONS: This trial will provide evidence on whether genistein supplementation may help slow cognitive decline and reduce amyloid burden in patients with MCI due to Alzheimer disease.

Parole chiave

HumansGenisteinAlzheimer DiseaseCognitive DysfunctionDouble-Blind MethodRandomized Controlled Trials as TopicDisease ProgressionDietary SupplementsMulticenter Studies as TopicFemaleAgedMaleMiddle AgedBiomarkersAlzheimer diseaseamyloid-betadementiagenisteinmild cognitive impairmentneuropsychological testsrandomized controlled trialsoy isoflavones
Leggi il testo integrale originale

Testo estratto dalla pubblicazione: sono esclusi immagini, media, supplementi e parti soggette a diritti distinti.

Effects of Supplementation With Genistein on the Progression of Cognitive Decline in Patients With Mild Cognitive Impairment Due to Alzheimer Disease: Protocol for a Randomized Controlled Trial

Abstract

Background

Mild cognitive impairment (MCI) may represent a prodromal stage of Alzheimer disease, but interventions to delay progression remain limited. Genistein is a phytoestrogenic isoflavone with potential effects on several pathways implicated in Alzheimer disease. We previously showed that genistein reverses cognitive decline and lowers brain amyloid β (Aβ) in the Aβ precursor protein/presenilin 1 double transgenic (AβPP/PS1) model of Alzheimer disease.

Objective

The study aimed to evaluate whether oral genistein supplementation affects cognitive decline in patients with MCI due to Alzheimer disease, compared with a placebo, and to assess its effects on brain amyloid burden and plasma biomarkers.

Methods

This multicenter, randomized, double-blind, placebo-controlled trial will include adults aged 50 years or older with MCI due to Alzheimer disease. Participants will be randomized 1:1 to genistein (200 mg/day) or a maltodextrin-based placebo for 18 months. The primary outcome is change in the Integrated Alzheimer’s Disease Rating Scale (iADRS) score. Secondary outcomes include other neuropsychological measures, amyloid burden measured by 18F-flutemetamol positron emission tomography, plasma Alzheimer disease biomarkers, and safety. Outcomes will be assessed at baseline, midstudy, and study completion. Analyses are planned in the intention-to-treat and per-protocol populations using repeated-measures analysis of variance, with time as the within-participant factor, treatment group as the between-participant factor, and study site as a covariate.

Results

Funding for the study began in January 2024 and was provided by Trugon Investigaciones (AIE) through a grant to the Chair of Geroscience at Universidad Católica de Murcia. Data collection began in July 2026 and is projected to conclude in January 2029, consistent with the estimated 30-month study duration. Enrollment is expected to last approximately 9 months. As of August 5, 2026, a total of 4 participants had been recruited. Data analysis has not begun and will start after the final participant completes follow-up. Results are expected to be published in late 2029.

Conclusions

This trial will provide evidence on whether genistein supplementation may help slow cognitive decline and reduce amyloid burden in patients with MCI due to Alzheimer disease.

Introduction

Background

Mild cognitive impairment (MCI) represents an intermediate stage between normal cognitive aging and established dementia. It is characterized by an objective decline in one or more cognitive domains, particularly memory, executive function, or language, that does not significantly interfere with the individual’s functional independence [1]. Longitudinal studies have shown that approximately 10% to 15% of patients with MCI progress to dementia each year, with Alzheimer disease being the most frequent cause [2]. However, this progression is not inevitable, as nearly 30% of cases remain stable, and about 15% show improvement or revert to normal or near-normal cognition [3]. This heterogeneity in the progression of MCI to clinically overt dementia has prompted the search for predictive biomarkers and, in particular, early interventions that may modify the natural course of the disease.

From a pathophysiological perspective, MCI associated with Alzheimer disease shares the same neurobiological substrates as established dementia, although to a lesser degree, including the accumulation of amyloid-β (Aβ) plaques, neurofibrillary tangles of hyperphosphorylated τ, oxidative stress, synaptic loss, and hippocampal atrophy [4]. The therapeutic window of MCI is particularly attractive because neuroprotective strategies may be more effective during this prodromal phase or preclinical stage, when neuronal damage is still limited [5]. However, over the past 20 years, advances in the search for effective treatments to modify the progression of Alzheimer disease have been modest. The clinical efficacy of treatments based on the intravenous administration of monoclonal antibodies targeting specific proteins involved in the pathophysiology of the disease, such as Aβ and phosphorylated τ, has been generally disappointing. Although antiamyloid therapies may slow disease progression, serious side effects such as amyloid‐related imaging abnormalities, edema, and hemorrhage are a matter of concern [6]. Moreover, the requirement for intravenous drug administration over prolonged periods complicates adherence to treatment. Clinical trials of antiamyloid agents in patients with MCI have shown contradictory results, highlighting the need to explore the effectiveness of additional drugs with broader pharmacological actions and more favorable safety profiles [7].

In this context, genistein, a phytoestrogenic isoflavone abundant in soy products, has emerged as a promising candidate due to its multimodal pharmacological properties. In contrast to conventional drugs that act on a single target, genistein exerts simultaneous effects on multiple underlying pathogenic pathways of MCI and Alzheimer disease [8]. This compound modulates Aβ metabolism and clearance from the brain. It binds to the peroxisome proliferator-activated receptor-γ (PPARγ) subunit of the retinoid X receptor–PPARγ heterodimer dimer, thus activating apolipoprotein E (ApoE) production, which in turn stimulates Aβ clearance from the brain [1]. Moreover, it inhibits β-secretase (BACE1) activity and stimulates Aβ degradation by activating neprilysin [9,10]. It also has anti-τ properties, reducing abnormal τ phosphorylation via inhibition of kinases like GSK-3β (glycogen synthase kinase-3β) [11], as well as mitochondrial neuroprotection by increasing the expression of superoxide dismutase 2 (SOD2) and catalase, antioxidant enzymes that mitigate oxidative stress [12]. Moreover, genistein exhibits anti-inflammatory effects by suppressing microglial activation and the production of proinflammatory cytokines (interleukin-6 [IL-6] and tumor necrosis factor-α [TNFα]), which are dependent on nuclear factor-kB (NF-kB) [13]. The cognitive-potentiating effects of genistein may be associated with improvements in synaptic plasticity, mediated by the positive regulation of brain-derived neurotrophic factor (BDNF) and N-methyl-d-aspartate (NMDA) receptors [14].

Rationale

Experimental studies have shown that genistein is useful to reverse the loss of cognition and pathological hallmarks in animal models of Alzheimer disease by targeting specific pathophysiological and signaling mechanisms involved in the neuropathology of the disease. In an Aβ precursor protein/presenilin 1 double transgenic (AβPP/PS1) mouse model, treatment with genistein resulted in a remarkable and rapid improvement in various parameters of cognition (such as hippocampal learning, recognition memory, implicit memory, and odor discrimination), which was associated with a lowering of Aβ levels in the brain, number and areas of amyloid plaques, and microglial reactivity [12]. This beneficial effect of genistein was mediated by a PPARγ-dependent increase in ApoE released from astrocytes [12]. In another rat model of Alzheimer disease, genistein showed neuroprotective effects by inhibiting the endoplasmic reticulum stress–mediated apoptotic pathway, reducing damage to hippocampal neurons and improving learning and memory [15]. Moreover, in streptozotocin (STZ)–treated male rats, a model of sporadic Alzheimer disease, high doses of genistein (150 mg/kg/day) normalized behavioral and biochemical deficits, with activation of autophagy appearing to be the primary mechanism [16]. Moreover, in vitro, neuronal models have shown the pleiotropic effects of genistein at intracellular and extracellular levels [17-19]. Taken together, this robust preclinical evidence of genistein’s pleiotropic effects on PPARγ supports the potential role of this naturally occurring compound in the therapeutic armamentarium for Alzheimer disease.

However, translation of experimental studies to humans is very limited and remains restricted to the preliminary results of a single clinical trial that we performed, in which 24 patients with prodromal Alzheimer disease were treated with 120 mg/day of genistein or a placebo for 24 months [20]. Aβ deposition was analyzed using 18F-flutemetamol uptake, and cognitive changes were assessed using a battery of neurocognitive tests. The main finding of the study was the lack of increase in Aβ uptake in the anterior cingulate gyrus in genistein-treated patients, compared with significant increases in the placebo group. Moreover, the results of neurocognitive tests showed an overall tendency toward improvement in the genistein group, reaching statistical significance in 2 of them (the dichotomized TAVEC [Aprendizaje Verbal España-Complutense Test] and Centil Rey Delayed Copy tests) vs placebo. A combined Alzheimer disease score, calculated from all 12 tests, showed a statistically significant improvement in individuals taking genistein compared with a placebo [20]. These preliminary positive findings in a small study population provide the basis for designing the present larger clinical trial with broader outcomes.

Objectives

The primary objective is to assess the effects of dietary supplementation with genistein on the progression of cognitive decline in patients diagnosed with MCI due to Alzheimer disease, compared with a placebo, after 18 months of treatment, in relation to the following functions: (1) global assessment of dementia: evaluation of overall functionality and cognitive decline in patients with MCI; (2) assessment of global cognitive functions; (3) assessment of episodic memory; (4) assessment of the patient’s ability to perform activities of daily living (basic or instrumental); and (5) assessment of depressive emotional status.

Secondary objectives are the following: (1) to assess changes in neurological clinical manifestations; (2) to assess changes in Aβ load on brain neuroimaging; (3) to assess the modifications produced by the investigational product on serum biomarkers of Alzheimer disease; and (4) to assess the safety of the investigational product.

Methods

Study Design and Patients

The proposed study is a multicenter, randomized, double-blind, placebo-controlled clinical trial with 2 parallel arms (experimental and placebo) to be conducted at the outpatient clinics of the neurology or geriatrics departments of secondary and tertiary care hospitals in the Spanish National Health System across the country. The trial design follows the SPIRIT (Standard Protocol Items: Recommendations for Interventional Trials) 2025 guidelines (Checklist 1 [21]). The trial report will adhere to the CONSORT (Consolidated Standards of Reporting Trials) guidelines [22].

Participants are patients aged 50 years or older diagnosed with MCI due to Alzheimer disease according to the criteria of the National Institute on Aging and Alzheimer Association [23] who meet the eligibility criteria and provide written informed consent. The inclusion and exclusion criteria are summarized in Textbox 1. The enrollment period is expected to last approximately 9 months from the first study visit. The follow-up period will extend for 18 months, with an estimated total study duration of 30 months.

Textbox 1.Eligibility criteria.

Inclusion criteria

Patients aged 50 years or older

Diagnosis of mild cognitive impairment due to Alzheimer disease according to criteria of the National Institute on Aging and Alzheimer’s Association [24]

A Mini-Mental State Examination score between 22 and 30 inclusive (exceptions can be made for patients with fewer than 5 years of formal education).

Evidence of concern for cognitive change compared to the person’s previous level (complaint/subjective memory impairment within the past year for more than 6 months and/or confirmed by the informant and/or the physician).

Clinical dementia rating of 0.5, with a score of 0.5 in the memory domain.

Essentially preserved activities of daily living.

Evidence of increased cortical amyloid as shown by 18F-flutemetamol positron emission tomography imaging.

Exclusion criteria

Diagnosis of a neurological disease other than Alzheimer disease.

Moderate depression using the Geriatric Depression Scale-15 with a score >8 or presence of any other severe psychiatric disorder.

Treatment with an acetylcholinesterase inhibitor and/or memantine in the past 3 months.

Use of isoflavones-containing supplements.

Presence of hormone-dependent neoplasms.

Diagnosis of significant cerebrovascular disease.

Presence of any severe systemic disease preventing completion of the study.

Refusal to provide the informed consent.

Ethical Considerations

The study adheres to the principles of the Declaration of Helsinki and Good Clinical Practice guidelines. The study protocol was approved by the Clinical Research Ethics Committee of Hospital Universitario de Getafe, Madrid (Spain; code 25/144, approval date: February 3, 2026) and Hospital Universitario de La Ribera, Alzira, Valencia (Spain; code MULT030226, approval date: March 31, 2026). Written informed consent will be obtained from all participants. To safeguard privacy, study data will be processed in accordance with the Spanish Data Protection Law 3/2018 [25], using a deidentified database to ensure full confidentiality. The trial is registered at ClinicalTrials.gov (NCT07385937).

Randomization and Blinding

A stratified randomization by center will be performed, with patients assigned in a 1:1 ratio to the experimental or placebo arms by a simple randomization procedure using the Epidat (version 4.2; Xunta de Galicia) software program. The randomization list will be maintained by a member of the research team who is independent of the study. The number of randomization codes allocated to each center will be determined by the anticipated patient recruitment. Recruitment will be competitive; therefore, if a center uses all of its assigned codes, additional codes will be issued from the general randomization list generated at the initiation of the study. After the randomization list is distributed to the centers, the principal investigator (PI) will be responsible for securely maintaining it and filing it in the investigator’s file, which will be kept at the research center.

This is a double-blind study aimed at minimizing bias, with patients and investigators blinded simultaneously to the patient’s treatment allocation. The investigational products will present the same organoleptic characteristics and will be labeled with the trial protocol number and each participant’s randomization code. Each eligible participant will be assigned a unique 5-character identification number: 2 letters for the center and 3 sequential digits corresponding to the assigned treatment number. In the case of a serious adverse event (AE) or an emergency requiring unblinding, the attending researcher must inform the PI, who will disclose the assigned treatment. All unblinding must be documented in the participant’s medical record and the electronic case report form.

Patient Withdrawal and Discontinuation

Participation in the study is voluntary, and no compensation will be offered. Patients may withdraw from the study at any time, without the need to provide a reason and without incurring any personal disadvantage. Patients who discontinue the study will not be replaced. The criteria for withdrawal include the following: protocol deviations, occurrence of AEs, the investigator’s decision, the patient’s refusal to continue the study, and loss to follow-up.

Intervention

Investigational Products

The experimental product is an encapsulated pure genistein powder extract, prepared by the Pharmacy Departments of Catholic University of Murcia (UCAM). The product was commercially acquired from the company South Sea Science Limited. UCAM has been exclusively responsible for the encapsulation process of the product to ensure proper blinding of the study, and the authors have no commercial associations with the intervention drug or its source.

Each capsule contains 100 mg of genistein, with a daily study dose of 200 mg, which is consistent with the safety, tolerability, and pharmacokinetics of single ascending doses of genistein reported in healthy volunteers [24]. Placebo capsules contain maltodextrin and are equal in shape and size to those of the investigational product. Patients will be instructed to take 2 capsules of the assigned product orally twice a day. It will be recommended to take each capsule about 30 minutes before breakfast and dinner, respectively, with a glass of water if needed. Participants will be advised to maintain their routine dietary habits and physical activity and not to initiate any drug treatment during the study unless fully justified and approved by the investigators.

Acquisition, Labeling, Storing, and Dispensing

The investigational products will be labeled in accordance with the Good Manufacturing Practice (GMP) guidelines for medicinal products for human and veterinary use. The label will include the batch number, the clinical trial reference code, the patients’ randomization code, the statement “for clinical trial use only,” the storage conditions, the shelf life (expiry date), and the statement “keep out of the reach of children.”

The investigational products will be available exclusively for this study and will remain under the responsibility of the PI at each study site for proper custody, storing under appropriate temperature and humidity conditions (at room temperature, preferably in a dry, cool place, and protected from direct sunlight), and dispensing to the study participants according to the randomization code list. Upon completion of the treatment period, the PI at each site will collect the returned capsules from participants and any remaining investigational products. Capsules returned by participants will be counted to assess compliance with treatment, defined as consumption of at least 80% of the assigned product.

Study Procedures

The study includes a screening (selection) visit (V0) and 7 study visits (V1-V7) scheduled along the 540 days of the study period, with a baseline visit (V1) and follow-up visits at 90±7 days (V2), 180±10 days (V3), 270±10 days (V4), 360±15 days (V5), 450±15 days (V6), and a final visit at 540±15 days (V7). The baseline visit and V3, V5, and V7 visits will be conducted face-to-face at the study center, whereas V2, V4, and V6 visits will be conducted by telephone.

At the screening visit (V0), which will take place within 60 days (8 weeks) prior to the baseline visit, the following activities will be performed: assessment of the inclusion criteria, obtaining informed consent after a full explanation of the objectives and characteristics of the study, randomization with assignment of the participant selection number, and scheduling an appointment for an 18F-flutemetamol positron emission tomography (18F-flutemetamol PET) scan.

The baseline visit (V1) involves assessing various study variables. The initial visit will take place on 3 days: on day 1, psychological tests will be administered to determine whether the individual meets the inclusion criteria. On day 2, the patients who pass the psychological tests will be analyzed (PET) for Aβ deposition in the brain. Those who are positive will pass the final psychological tests on day 3. The 3 days will not be more than 15 natural days apart. On the first day, the patient’s eligibility criteria and results of the 18F-flutemetamol PET scan will be checked. Data recorded will include demographics (age and sex), body weight, BMI, tobacco use, alcohol consumption, comorbidities, and concomitant medications. A first battery of neuropsychological tests will be completed. The hierarchical order of neuropsychological tests at the baseline visit on day 1 includes the following: (1) Mini-Mental State Examination (MMSE) scale; (2) Geriatric Depression Scale-15 (short version GDS-15); (3) Clinical Dementia Rating–Sum of Boxes (CDR-SB) scale; (4) Integrated Alzheimer’s Disease Rating Scale (iADRS); (5) Alzheimer’s Disease Cooperative Study–Activities of Daily Living for Mild Cognitive Impairment (ADCS-ADL-MCI) scale; and (6) Disability Assessment for Dementia (DAD-E) scale.

The hierarchical order of neuropsychological tests at the baseline visit on day 2 includes the following: (1) TAVEC; (2) Trail Making test (parts A and B); (3) clock drawing test (CDT); (4) Rey-Osterrieth Complex Figure (ROCF) test; (5) digit span test-forward and backward; (6) verbal fluency test; and (7) Frontal Assessment Battery (FAB).

Other procedures include fasting blood sampling for hematological and biochemical tests, including biomarkers of dementia, and provision of the study product for the first 6 months (180 days) of supplementation. Patients will be clearly instructed on how to take the study product, the importance of adhering to the treatment, and how to strictly maintain their dietary and lifestyle habits throughout the study. They will also be advised not to make any changes to their concurrent medications.

At visit 2 (via telephone), AEs will be recorded, concomitant medications with potential treatment changes will be checked, and visit 3 will be scheduled for 180±10 days. At visit 3, the same procedures as those performed at visit 1 (except for neuropsychological testing) and at visit 2 will be carried out. In addition, the study product for the following 6 months (180 days) of treatment will be dispensed; capsules returned from those given at visit 1 will be counted to assess compliance; and visit 4 at 270±10 days will be scheduled. At visit 4 (via telephone), the same procedures as at visit 2 will be followed, and visit 5 will be scheduled for 360±14 days. At visit 5, the same procedures as at the baseline visit will be performed. The battery of neuropsychological tests will be administered following the same hierarchy as at the baseline visit (V1). Assessment of AEs and concomitant medication, provision of the study product for the final 6 months (180 days) of treatment, and collection and counting of returned capsules will be performed. Also, visit 6 at 450±15 days will be scheduled. At visit 6 (via telephone), the same procedures as at visits 2 and 4 will be followed.

The final visit (V7) at the end of the study, at 540±15 days, will include a complete assessment of patients, including medical history; the battery of all neuropsychological tests was administered following the same hierarchy as in the baseline visit (V1) and visit 5 (V5), blood sampling for laboratory tests, evaluation of AEs and concomitant medication, collection and counting of the study product, and performance of an 18F-flutemetamol PET scan. A summary of the study design and procedures is shown in Figure 1. An overview of the study is shown in Table 1.

Table 1. Overview of the study.

Procedures V0a (selection) V1 (baseline) V2 (telephone; (90 days) V3 (180 days) V4 (telephone; (270 days) V5 (360 days) V6 (telephone) V7 (final visit; (540 days)

Eligibility, informed consent, and randomization ✓

Neuropsychological tests ✓ ✓ ✓

PETb ✓ ✓

Blood extraction ✓ ✓ ✓

Product delivery/return Delivery Both Both Return

Concomitant medication ✓ ✓ ✓ ✓ ✓ ✓

Adverse events ✓ ✓ ✓ ✓ ✓ ✓

aV: visit.

bPET: positron emission tomography.

Variables and Data Collection

Neuropsychological Tests

Evaluation of Cognition Impairment, Activities of Daily Living, and Depression

The iADRS combines scores from 2 widely accepted measures, the Alzheimer’s Disease Assessment Scale–Cognitive Subscale (ADAS-Cog) [26] and the Alzheimer’s Disease Cooperative Study–Instrumental Activities of Daily Living (ADCS-iADL) [27]. The iADRS [27] is calculated as a linear combination of the total scores of the 2 components: the Alzheimer’s Disease Assessment Scale–Cognitive Subscale, 14-item version (ADAS-Cog14; score range 0-90) and the instrumental items of the ADCS-iADL (score range 0-56). Because higher scores on the ADAS-Cog14 reflect worse performance, whereas higher scores on the ADCS-iADL reflect better performance, the ADAS-Cog score is multiplied by (−1) in the calculation of the integrated scale. To anchor the ADAS-Cog at 0, a constant (90) is added. The iADRS score is then computed as the sum of the transformed ADAS-Cog14 and the ADCS-iADL, as shown in the formula below:

iADRS score=[−1(ADAS-Cog14)+90]+ADCS-iADLThe iADRS score ranges from 0 to 146, with lower scores indicating worse performance [28]. The iADRS takes 25 to 30 minutes to complete. The ADAS-Cog is validated in Spanish [29].

The CDR-SB [30] is a semistructured interview used to assess the global severity of cognitive impairment and functional decline in conditions such as Alzheimer disease. It involves interviewing both the patient and a caregiver to assess 6 domains: memory, orientation, judgment and problem-solving, community affairs, home and hobbies, and personal care. The CDR-SB total score ranges from 0 to 18, with the global severity of cognitive impairment categorized as 0: normal, 0.5: very mild (questionable cognitive impairment to very mild dementia), 1: mild (suggests mild dementia), 2: moderate (suggests moderate dementia), and 3: severe (suggests severe dementia) [31]. It takes 20 to 25 minutes to complete.

The ADCS-ADL-MCI [32] is a functional evaluation scale that assesses the ability of patients to perform activities of daily living (ADLs), with recall “in the past 4 weeks,” through a structured questionnaire administered to the informant/caregiver by a physician or qualified rater. The ADCS-ADL-MCI was derived from its parent measure, the ADCS-ADL, and adapted for patients with MCI. There are 2 forms of the ADCS-ADL-MCI, the 24-item and the 18-item versions. The 18-item ADCS-ADL-MCI [33], commonly used in clinical trials and clinical practice, is scored from 0 to 53 based on the patients’ degree of independence (from 0: fully dependent to 3: fully independent) in performing a wide range of activities, from basic personal care (eg, getting dressed, selecting one’s clothes, doing the laundry, making a meal, etc) to instrumental ADLs (eg, using a telephone, balancing the checkbox, writing notes, traveling out of home, etc). Higher ADCS-ADL-MCI scores indicate better functional abilities. It takes 15 to 25 minutes to complete.

The DAD-E [34] is a 40-item questionnaire designed to evaluate both basic and instrumental ADLs in patients with cognitive impairment. The scale is completed by a caregiver or proxy respondent, with recall “in the past 2 weeks.” Basic ADLs are dressing, hygiene, continence, eating, meal preparation, and telephoning, whereas instrumental activities include going out and outing, finance and correspondence, medications, and leisure and housework. The choice of answer is 1 point: yes (the person performs the activity without help or reminder); 0 points: no (the person performs the activity with some verbal or physical assistance from the caregiver); and N/A: not applicable (the person never did this activity or did not have the opportunity to do it in the past 2 weeks). The final score ranges from 0 to 80, with higher scores indicating greater functional independence and lower disability. A DAD score of 70 to 80 suggests no significant cognitive decline; a score of 60 to 70 indicates MCI; and a score <60 indicates mild to moderate dementia. The DAD instrument has been validated in Spanish [35] and takes 5 to 10 minutes to complete.

The GDS-15 is used to screen for depression in older adults and consists of 15 items that assess mental health based on feelings over the past week. Although it is not designed for the diagnosis of Alzheimer disease, it is useful to detect depressive symptoms that may coexist with dementia or affect quality of life. Examinees are asked to respond “yes” or “no” to each item in reference to the past week. One point is given for depressive responses. All responses are summed to calculate the final score, which ranges from 0 to 15. Scores ranging from 0 to 4 are classified as within normal limits, 5 to 9 as mild depressive symptoms, and 10 to 15 as moderate-to-severe [36]. A Spanish validated version of the GDS-15 scale is available [37]. It takes 5 to 10 minutes to complete.

The MMSE test is one of the most commonly used tools for the detection and evaluation of cognitive impairment, including Alzheimer disease. It is an 11-question measure that tests 5 areas of cognitive function: orientation (10 points), registration (3 points), attention and calculation (5 points), recall (3 points), and language and praxis (9 points). The maximum score is 30, with scores 27 to 30 indicating normal cognition, 24 to 26 indicating MCI, 20 to 23 indicating moderate impairment, and <20 indicating severe impairment. Since the original description in 1975 [38], the MMSE has been validated in many languages, including Spanish [39], and is extensively used in both clinical practice and research. Setting the upper limit at 30 addresses the MMSE’s ceiling effect, as individuals with high cognitive reserve or early-stage MCI can achieve normative scores (27/30) without ruling out actual cognitive impairment. Conversely, the lower limit of 22 allows for the detection of more advanced MCI or moderate dementia.

Evaluation of Episodic Memory and Delayed Recall

The TAVEC is the Spanish adaptation of the California Verbal Learning Test (CVLT) [40] and is widely used in Spanish-speaking populations [41]. It evaluates verbal episodic memory and learning capacity and comprises 5 phases: learning, interference, immediate recall, delayed recall, and recognition, using 2 different lists of 16 words (A and B). During the learning phase, a 16-word list (list A) is read aloud to the patients 5 times, and the number of words remembered is recorded. In healthy individuals, the expected total score is 40 to 50 words, whereas in Alzheimer disease, a score ≤30 may be expected. In the interference phase, another 16-word list (list B) is presented, and the number of words remembered and the scoring procedure are the same as in the learning phase. In the immediate recall phase, the participant is asked to recall the words from list A; normally, 8 to 10 words are remembered, and recalling ≤5 suggests difficulty in overcoming interference, as seen in Alzheimer disease. In the delayed recall phase, list B is used, and the same procedures as in the immediate recall phase are followed. In the final recognition phase, a list of 44 words is presented, including lists A and B and 12 new words (distractors), and the participant should identify words belonging to list A. The recognition phase is scored as the number of correct words minus the number of false positives (confusion with words that were not presented), with a score <0.7 suggesting Alzheimer disease. The TAVEC test takes 40 to 45 minutes to administer.

The ROCF test [42,43] involves the immediate copying of complex geometric shapes and a delayed recall (30 minutes). Scoring is based on a system of 18 elements that evaluates both the accuracy and organization of the drawing, with each element rated as 0 (absent or incorrect), 1 (partially correct), or 2 (correct), yielding a total score ranging from 0 to 36 points. Patients with Alzheimer disease may present difficulties in copying, reflecting impairments in visuospatial perception and visuo-constructive organization, as well as deficits in recalling, reflecting problems with visual memory and retention of information.

In the delayed recall phase of the ROFC test, 30 minutes after the initial copy, patients will be asked to reproduce the figure from memory, with performance scored using the same 18-element system as the immediate copy, evaluating both accuracy and organization. Moreover, the delayed recall and recognition phases of the TAVEC will also be repeated.

Evaluation of Executive/Attention Functions

The CDT will be used to quickly assess visuospatial and praxis abilities and may be useful for identifying both attentional and executive dysfunction [44]. Typically, patients are asked to draw a clock face, fill in all the numbers, and then set the hands to a specific time, most commonly “10 minutes after 11.” It takes 5 to 10 minutes to complete.

The Digit Span Test will be used in 2 formats: forward digit span and reverse digit span. Participants are presented with a random series of digits and are asked to repeat them in either the order presented (forward span) or in reverse order (backward span) [45]. Forward and backward formats rely on somewhat separable cognitive capacities: the simpler forward span task requires verbal working memory and attention, while the backward span task additionally tests cognitive control and executive function. Forward span scores typically range from 7 to 9 digits, whereas backward span scores range from 5 to 6 digits. Scores are usually lower in the context of Alzheimer disease. The test takes 5 to 10 minutes to complete.

The Trail Making test (parts A and B) involves visual scanning and working memory. Each part consists of 25 circles distributed over a sheet of paper [46]. In Part A, the circles are numbered 1 to 25, and the patient should draw lines to connect the numbers in ascending order, whereas in part B, the circles include both numbers (1-13) and letters (A-L) and the patient draws lines to connect the circles in an ascending pattern, but with the added task of alternating between the numbers and letters (ie, 1-A-2-B-3-C, etc). Results are reported as the time required to complete the task, with higher scores indicating greater impairment. Completion times for part A typically range from 40 to 60 seconds for cognitively healthy older adults, whereas part B averages between 60 and 90 seconds. Administration of the Trail Making test (parts A and B) takes 5 minutes.

The FAB is a brief tool that helps to assist in discriminating between dementias with a frontal dysexecutive phenotype and dementia of Alzheimer type [47]. It consists of 6 tests that correspond to each specific cognitive or behavioral domain related to the frontal lobes. The 6 domains are similarities (conceptualization), lexical fluency (mental flexibility), motor series (programming), contradictory instructions (sensitivity to interferences), Go/No-Go (inhibitory control), and prehension (grasp) behavior (environmental autonomy). Scores range from 0 to 18, with higher scores indicating better performance. Scores of 17 to 18 are considered normal, scores of 12 to 16 indicate mild impairment, scores of 9 to 11 indicate moderate impairment, and scores of 0 to 8 indicate severe impairment. A validated Spanish version of the FAB will be used [48]. The test takes 10 to 20 minutes to complete.

18F-Flutemetamol PET Imaging

Radioligands, such as 18F-flutemetamol, selectively bind to Aβ, allowing direct PET imaging of Aβ plaques in patients with Alzheimer disease [49]. Quantification of Aβ PET radioligand retention can detect changes in brain Aβ plaque burden over time. Amyloid-PET images will be acquired 90 minutes after the intravenous administration of the 18F-flutemetamol tracer (185 MBq). Standardized uptake values (SUVs) are commonly used as semiquantitative measures of Aβ burden, calculated by normalizing Aβ PET radiotracer retention in a target brain region of interest to a reference region not expected to accumulate amyloid. The SUVs from a set of selected brain regions are averaged to compute a composite SUV. Higher composite SUV values indicate a greater amyloid burden, and negative changes in the composite cortical SUV over time indicate decreases in cerebral amyloid burden.

Serum Biomarkers

Evaluation of serum biomarkers can provide a more comprehensive perspective on underlying mechanisms and treatment response. Aβ peptides (Aβ1‐42 and Aβ1‐40), phosphorylated τ protein (p-tau181 and p-tau217), neurofilament light chain (NfL), and BDNF will be measured centrally at the laboratory facilities of “Pasqual Maragall Foundation” (Barcelona, Spain). Inflammatory markers, including C-reactive protein (CRP), IL-6, and TNFα, will be measured using analytical techniques available in the laboratories of the participating hospitals, following the manufacturers’ instructions when commercial kits are used.

Safety Assessments

Safety outcomes will include spontaneously reported AEs, vital signs, physical examination, and results of laboratory tests, including blood cell count, liver function tests (aminotransferases [alanine aminotransferase (ALT) and aspartate aminotransferase (AST)], bilirubin, γ-glutamyl transpeptidase [GGT], lactate dehydrogenase [LDH]), renal function tests (blood urea nitrogen and creatinine clearance), and urinalysis.

Evaluation Outcomes

The primary outcome of the study is the mean change in the iADRS score after 18 months of genistein consumption relative to baseline. The iADRS integrates global cognition results (ADAS-Cog 14) with results from activities of daily living (ADCS-ADL), thereby providing a comprehensive view of the patient’s cognitive and functional status.

Secondary outcomes include the mean changes in scores for the remaining neuropsychological tests at the end of the study relative to baseline, the reduction in amyloid plaque as assessed by 18F-flutemetamol PTC, and changes in biomarkers of Alzheimer disease. Neuropsychological tests prioritized as secondary outcomes were the MMSE, TAVEC, CDT, and ROCF, as these tests were evaluated in a previous study by our group [20].

Statistical Analyses

Sample Size Estimation

The sample size was calculated based on the least-squares mean change in the iADRS score as the primary outcome of the study. Considering an SD of 1.56 for the least-squares mean change in the iADRS score at 76 weeks, obtained in a similar population of patients with Alzheimer disease [50], for a precision of 0.7 with an α level of 5% and statistical power of 80%, 61 patients per study group will be required, increasing to 82 patients per group assuming a 25% loss to follow-up.

Data Analysis

Analyzes will be performed across 2 datasets: the per-protocol population (ie, patients who completed the 18 month study period) and the intention-to-treat population (ie, all randomized patients who received at least one dose of the assigned treatment and attended at least one follow-up visit). Categorical variables are described as frequencies and percentages, and continuous variables as means, medians, SDs, 95% CIs, and ranges (minimum and maximum) for the overall study population and the experimental and placebo groups. To ensure comparability of baseline characteristics between the 2 study groups, categorical variables will be analyzed using the chi-square test or Fisher exact test, as appropriate, and continuous variables will be analyzed using the Student 2-tailed t test. Changes in study variables over the course of the study will then be evaluated using a repeated-measures ANOVA, with time as the within-participant factor, product (genistein or placebo) as the between-participant factor, and study site as a covariate. Tukey or Bonferroni correction procedures will be applied for post hoc analyses. The analysis of the intention-to-treat population will account for patients lost to follow-up. In the analysis of the per-protocol population, the last observation carried forward method will be used to handle missing data. Statistical significance is set at P<0.05. SPSS (version 21.0; IBM Corp) will be used to analyze the data. No interim analyzes are planned.

Results

Funding for the study began in January 2024 and was provided by Trugon Investigaciones (AIE) through a grant to the Chair of Geroscience at Universidad Católica de Murcia. Data collection began in July 2026 and is projected to conclude in January 2029, consistent with the estimated 30-month study duration. Enrollment is expected to last approximately 9 months from the first study visit, which took place in July 2026. As of August 5, 2026, a total of 4 participants had been recruited. The follow-up period will extend for 18 months, with an estimated total study duration of 30 months. Data analysis has not begun and will start after the final participant completes follow-up, and the results of these analyses are expected to be published in late 2029.

Discussion

Principal Findings

MCI is a nosological entity proposed as an intermediate state between normal aging and dementia and frequently appears to represent an early stage of Alzheimer disease. However, the prognosis of MCI, the conversion risk to dementia, and the probability of stability or reversion are still under intense study. Data from a comprehensive systematic review and meta-analysis of 66 clinical-based studies, including a population of 21,822 participants with a diagnosis of MCI, reported a risk of conversion to dementia of 41.5% (95% CI 38.3%‐44.7%) [51]. Interestingly, the study highlights the need for specific MCI management, as follow-up length did not affect conversion risk, suggesting a slower or plateauing neurodegenerative process over time [50]. Thus, interventions that may improve cognition or delay the progression of cognitive decline represent a crucial step in the prognosis of mild neurocognitive disorders. Moreover, recent epidemiological data of Alzheimer disease alert the public health impact of the disease, with a number of 7.2 million Americans aged 65 years or older living with Alzheimer dementia today, and this number is expected to grow to 13.8 million by 2060 [52].

The present project aligns with the current research focus on Alzheimer disease: developing patient-centered, nonpharmacological interventions to slow its progression, which are crucial for managing symptoms, improving quality of life, and preserving independence. When developing the study, we paid particular attention to selecting the primary outcome. The iADRS is scientifically robust, has already been used in clinical trials of antiamyloid treatments for Alzheimer disease, and has been proven to be a sensitive and reliable tool capable of measuring the effectiveness of treatment on cognition and ADLs [50]. Moreover, the use of 18F-flutemetamol PET to monitor disease progression by demonstrating amyloid plaque load will help evaluate the effectiveness of genistein by tracking changes in amyloid deposition over time.

Limitations

Although every effort will be made to administer the complete battery of psychoneurological tests at visits 5 and 7 (360 and 540 d after study initiation), the large number of assessments makes it difficult to ensure complete adherence to this procedure. To mitigate this potential limitation, the importance of completing the full battery of tests will be emphasized during the preceding telephone visits (visits 4 and 6).

Conclusions

The proposed trial will be the first to evaluate the effects of oral supplementation with a natural extract of genistein on the progression of cognitive decline and activities of daily living in patients diagnosed with MCI due to Alzheimer disease, based on an extensive battery of neuropsychological tests, the assessment of amyloid plaques by neuroimaging, and measurements of serum levels of Alzheimer disease biomarkers. The observation of beneficial changes in the study variables after 18 months of genistein supplementation would be highly relevant from a clinical perspective, given the overwhelming health care and societal burden of dementia and the fact that genistein is an inexpensive and readily available natural compound. So far, however, the favorable effects of genistein in MCI remain preliminary, and the primary aim of this clinical trial is to determine whether genistein is capable of delaying the progression of cognitive decline in patients with MCI.

Supplementary material

References

1.Petersen RC Lopez O Armstrong MJ et alPractice guideline update summary: mild cognitive impairment [RETIRED]: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology Neurology 01162018 90 3 126 135 doi10.1212/WNL.0000000000004826 Medline29282327 PMC5772157

2.Sanford AM Mild cognitive impairment Clin Geriatr Med Aug2017 33 3 325 337 doi10.1016/j.cger.2017.02.005 Medline28689566

3.Koepsell TD Monsell SE Reversion from mild cognitive impairment to normal or near-normal cognition: risk factors and prognosis Neurology Oct92012 79 15 1591 1598 doi10.1212/WNL.0b013e31826e26b7 Medline23019264 PMC3475624

4.Jack Jr CR JrBennett DA Blennow K et alNIA-AA research framework: toward a biological definition of Alzheimer’s disease Alzheimers Dement Apr2018 14 4 535 562 doi10.1016/j.jalz.2018.02.018 Medline29653606 PMC5958625

5.Sperling RA Aisen PS Beckett LA et alToward defining the preclinical stages of Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease Alzheimers Dement 052011 7 3 280 292 doi10.1016/j.jalz.2011.03.003 Medline21514248 PMC3220946

6.Doran SJ Sawyer RP Risk factors in developing amyloid related imaging abnormalities (ARIA) and clinical implications Front Neurosci 2024 18 1326784doi10.3389/fnins.2024.1326784 Medline38312931 PMC10834650

7.Egan MF Kost J Voss T et alRandomized trial of verubecestat for prodromal Alzheimer’s disease N Engl J Med Apr112019 380 15 1408 1420 doi10.1056/NEJMoa1812840 Medline30970186 PMC6776078

8.Mas-Bargues C Borrás C Viña J The multimodal action of genistein in Alzheimer’s and other age-related diseases Free Radic Biol Med Apr2022 183 127 137 doi10.1016/j.freeradbiomed.2022.03.021 Medline35346775

9.Patel S Bansoad AV Singh R Khatik GL BACE1: a key regulator in Alzheimer’s disease progression and current development of its inhibitors Curr Neuropharmacol 2022 20 6 1174 1193 doi10.2174/1570159X19666211201094031 Medline34852746 PMC9886827

10.Rofo F Metzendorf NG Saubi C et alBlood-brain barrier penetrating neprilysin degrades monomeric amyloid-beta in a mouse model of Alzheimer’s disease Alzheimers Res Ther Dec52022 14 1 180doi10.1186/s13195-022-01132-2 Medline36471433 PMC9720954

11.Rankin CA Sun Q Gamblin TC Tau phosphorylation by GSK-3beta promotes tangle-like filament morphology Mol Neurodegener Jun282007 2 12doi10.1186/1750-1326-2-12 Medline17598919 PMC1936422

12.Bonet-Costa V Herranz-Pérez V Blanco-Gandía M et alClearing amyloid-β through PPARγ/ApoE activation by genistein is a treatment of experimental Alzheimer’s disease J Alzheimers Dis 2016 51 3 701 711 doi10.3233/JAD-151020 Medline26890773

13.Shen J Ji XZ Han L et alActivation of NF-κB/MAPK signaling and induction of apoptosis by salicylate synthase NbtS in Nocardia farcinica promotes neuroinflammation development mSystems Oct222024 9 10 e0089324doi10.1128/msystems.00893-24 Medline39240104 PMC11494946

14.Levine ES Crozier RA Black IB Plummer MR Brain-derived neurotrophic factor modulates hippocampal synaptic transmission by increasing N-methyl-D-aspartic acid receptor activity Proc Natl Acad Sci U S A Aug181998 95 17 10235 10239 doi10.1073/pnas.95.17.10235 Medline9707630 PMC21491

15.Gao H Lei X Ye S et alCorrigendum to “Genistein attenuates memory impairment in Alzheimer’s disease via ERS-mediated apoptotic pathway in vivo and in vitro” [The Journal of Nutritional Biochemistry Volume 109 (2022) 109118] J Nutr Biochem Sep2024 131 109710 doi10.1016/j.jnutbio.2024.109710 Medline39094353

16.Pierzynowska K Podlacha M Gaffke L et alAutophagy-dependent mechanism of genistein-mediated elimination of behavioral and biochemical defects in the rat model of sporadic Alzheimer’s disease Neuropharmacology Apr2019 148 332 346 doi10.1016/j.neuropharm.2019.01.030 Medline30710571

17.Guo J Yang G He Y et alInvolvement of α7nAChR in the protective effects of genistein against β-amyloid-induced oxidative stress in neurons via a PI3K/Akt/Nrf2 pathway-related mechanism Cell Mol Neurobiol Mar2021 41 2 377 393 doi10.1007/s10571-020-01009-8 Medline33215356 PMC11448600

18.Duan X Li Y Xu F Ding H Study on the neuroprotective effects of genistein on Alzheimer’s disease Brain Behav 052021 11 5 e02100doi10.1002/brb3.2100 Medline33704934 PMC8119804

19.Zhang K Wang J Xu B Critical review on molecular mechanisms for genistein’s beneficial effects on health through oxidative stress reduction Antioxidants (Basel) 07242025 14 8 904doi10.3390/antiox14080904 Medline40867803 PMC12382804

20.Viña J Escudero J Baquero M et alGenistein effect on cognition in prodromal Alzheimer’s disease patients. The GENIAL clinical trial Alzheimers Res Ther Nov42022 14 1 164doi10.1186/s13195-022-01097-2 Medline36329553 PMC9635167

21.Chan AW Boutron I Hopewell S et alSPIRIT 2025 statement: updated guideline for protocols of randomized trials Nat Med Jun2025 31 6 1784 1792 doi10.1038/s41591-025-03668-w Medline40295741

22.Hopewell S Chan AW Collins GS et alCONSORT 2025 statement: updated guideline for reporting randomised trials BMJ Apr142025 389 e081123doi10.1136/bmj-2024-081123 Medline40228833 PMC11995449

23.Jack Jr CR JrAndrews JS Beach TG et alRevised criteria for diagnosis and staging of Alzheimer’s disease: Alzheimer’s Association Workgroup Alzheimers Dement Aug2024 20 8 5143 5169 doi10.1002/alz.13859 Medline38934362 PMC11350039

24.Ullmann U Metzner J Frank T Cohn W Riegger C Safety, tolerability, and pharmacokinetics of single ascending doses of synthetic genistein (Bonistein) in healthy volunteers Adv Ther 2005 22 1 65 78 doi10.1007/BF02850186 Medline15943224

25.Ley Orgánica 3/2018, de 5 de diciembre, de Protección de Datos Personales y garantía de los derechos digitales [Article in Spanish] Boletín Oficial del Estado Dec62018 URLhttps://www.boe.es/buscar/act.php?id=BOE-A-2018-16673Accessed26-10-2026

26.Raghavan N Samtani MN Farnum M et alThe ADAS-Cog revisited: novel composite scales based on ADAS-Cog to improve efficiency in MCI and early AD trials Alzheimers Dement Feb2013 9 1 Suppl S21 S31 doi10.1016/j.jalz.2012.05.2187 Medline23127469 PMC3732822

27.Galasko D Bennett D Sano M et alAn inventory to assess activities of daily living for clinical trials in Alzheimerʼs disease Alzheimer Dis Assoc Disord 1997 11 33 39 doi10.1097/00002093-199700112-00005

28.Wessels AM Siemers ER Yu P et alA combined measure of cognition and function for clinical trials: the Integrated Alzheimer’s Disease Rating Scale (iADRS) J Prev Alzheimers Dis Dec12015 2 4 227 241 doi10.14283/jpad.2015.82 Medline27019841 PMC4806404

29.Peña-Casanova J Aguilar M Bertran-Serra I et alNormalization of cognitive and functional assessment instruments for dementia (NORMACODEM) (I): objectives, content and population [Article in Spanish] Neurologia Feb1997 12 2 61 68 Medline9147453

30.Morris JC The Clinical Dementia Rating (CDR): current version and scoring rules Neurology Nov1993 43 11 2412 2414 doi10.1212/wnl.43.11.2412-a Medline8232972

31.O’Bryant SE Waring SC Cullum CM et alStaging dementia using Clinical Dementia Rating Scale Sum of Boxes scores: a Texas Alzheimer’s research consortium study Arch Neurol Aug2008 65 8 1091 1095 doi10.1001/archneur.65.8.1091 Medline18695059 PMC3409562

32.Pedrosa H De Sa A Guerreiro M et alFunctional evaluation distinguishes MCI patients from healthy elderly people--the ADCS/MCI/ADL scale J Nutr Health Aging Oct2010 14 8 703 709 doi10.1007/s12603-010-0102-1 Medline20922349 PMC12880264

33.Potashman M Pang M Tahir M et alPsychometric properties of the Alzheimer’s Disease Cooperative Study - Activities of Daily Living for Mild Cognitive Impairment (ADCS-MCI-ADL) scale: a post hoc analysis of the ADCS ADC-008 trial BMC Geriatr Mar62023 23 1 124doi10.1186/s12877-022-03527-0 Medline36879199 PMC9990271

34.Sánchez-Pérez A López-Roig S Pampliega Pérez A Peral Gómez P Pastor MÁ Hurtado-Pomares M Translation and adaptation of the Disability Assessment for Dementia scale in the Spanish population [Article in English, Spanish] Med Clin (Barc) Sep2017 149 6 248 252 doi10.1016/j.medcli.2017.03.029 Medline28527600

35.Sánchez-Pérez A López-Roig S Pérez AP Gómez PP Pastor MÁ Pomares MH Validation study of the Spanish version of the Disability Assessment for Dementia Scale Medicine (Baltimore) Nov2015 94 44 e1925doi10.1097/MD.0000000000001925 Medline26554794 PMC4915895

36.Yesavage JA Sheikh JI Geriatric Depression Scale (GDS): recent evidence and development of a shorter version Clin Gerontologist 1986 5 165 173 doi10.1300/J018v05n01_09

37.Lucas-Carrasco R Spanish version of the Geriatric Depression Scale: reliability and validity in persons with mild-moderate dementia Int Psychogeriatr Aug2012 24 8 1284 1290 doi10.1017/S1041610212000336 Medline22475132

38.Folstein MF Folstein SE McHugh PR “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician J Psychiatr Res Nov1975 12 3 189 198 doi10.1016/0022-3956(75)90026-6 Medline1202204

39.de Beaman SR Beaman PE Garcia-Peña C et alValidation of a modified version of the Mini-Mental State Examination (MMSE) in Spanish Aging Neuropsychol Cogn Mar2004 11 1 1 11 doi10.1076/anec.11.1.1.29366

40.Elwood RW The California Verbal Learning Test: psychometric characteristics and clinical application Neuropsychol Rev Sep1995 5 3 173 201 doi10.1007/BF02214761 Medline8653108

41.Benedet MJ Alejandre MA TAVEC: Test de Aprendizaje Verbal España-Complutense [Book in Spanish] 2ndTEA Ediciones1998 URLhttps://hogrefe-tea.com/recursos/Ejemplos/TAVEC-Manual-Extracto.pdfAccessed15-10-2026

42.Boone KB Lesser IM Hill-gutierrez E Berman NG D’elia LF Rey-osterrieth complex figure performance in healthy, older adults: relationship to age, education, sex, and IQ Clin Neuropsychol 011993 7 1 22 28 doi10.1080/13854049308401884

43.Zhang X Lv L Min G Wang Q Zhao Y Li Y Overview of the complex figure test and its clinical application in neuropsychiatric disorders, including copying and recall Front Neurol 2021 12 680474doi10.3389/fneur.2021.680474 Medline34531812 PMC8438146

44.Cacho J García-García R Arcaya J Vicente JL Lantada N A proposal for application and scoring of the Clock Drawing Test in Alzheimer’s disease [Article in Spanish] Rev Neurol 1999 28 7 648 655 doi10.33588/rn.2807.98501 Medline10363287

45.Hester RL Kinsella GJ Ong B Effect of age on forward and backward span tasks J Int Neuropsychol Soc 072004 10 4 475 481 doi10.1017/S1355617704104037 Medline15327726

46.Bowie CR Harvey PD Administration and interpretation of the Trail Making Test Nat Protoc 2006 1 5 2277 2281 doi10.1038/nprot.2006.390 Medline17406468

47.Dubois B Slachevsky A Litvan I Pillon B The FAB: a frontal assessment battery at bedside Neurology Dec122000 55 11 1621 1626 doi10.1212/wnl.55.11.1621 Medline11113214

48.Hurtado-Pomares M Valera-Gran D Sánchez-Pérez A Peral-Gómez P Navarrete-Muñoz EM Terol-Cantero MC Adaptation of the Spanish version of the Frontal Assessment Battery for detection of executive dysfunction [Article in English, Spanish] Med Clin (Barc) Mar122021 156 5 229 232 doi10.1016/j.medcli.2020.04.028 Medline32919777

49.Veljanoska E Gomes S Szende A Cabra A Munter-Young R Gordois A The value of positron emission tomography for confirmation of Alzheimer’s disease in the era of amyloid-targeting therapies Value Health Jun2025 28 6 829 838 doi10.1016/j.jval.2025.02.011 Medline40054769

50.Mintun MA Lo AC Duggan Evans C et alDonanemab in early Alzheimer’s disease N Engl J Med 0562021 384 18 1691 1704 doi10.1056/NEJMoa2100708 Medline33720637

51.Correction to “The prognosis of mild cognitive impairment: a systematic review and meta-analysis” Alzheimers Dement (Amst) 07182025 17 3 e70150doi10.1002/dad2.70150 Medline40689335 PMC12271972

52.2025 Alzheimer’s disease facts and figures Alzheimers Dement 2025 21 4 e70235doi10.1002/alz.70235

Come citare questo studio

Francisco Javier López Román, Manuel Sebastián, Silvia Pérez-Piñero, Ingrid Hernández-Manzano, Olga Laosa-Zafra, Leocadio Rodríguez-Mañas, Francisco José Tarazona-Santabalbina, Consuelo Borrás, José Viña. (2026). Effects of Supplementation With Genistein on the Progression of Cognitive Decline in Patients With Mild Cognitive Impairment Due to Alzheimer Disease: Protocol for a Randomized Controlled Trial.. JMIR research protocols. DOI: 10.2196/98087

Consulta la pubblicazione originale ↗